These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 25025958)

  • 21. Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.
    Harbeck N; Wuerstlein R
    Drugs; 2013 Oct; 73(15):1665-80. PubMed ID: 24127221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
    Awada G; Gombos A; Aftimos P; Awada A
    Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
    Nuciforo PG; Aura C; Holmes E; Prudkin L; Jimenez J; Martinez P; Ameels H; de la Peña L; Ellis C; Eidtmann H; Piccart-Gebhart MJ; Scaltriti M; Baselga J
    Ann Oncol; 2015 Jul; 26(7):1494-500. PubMed ID: 25851628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer.
    Janjigian YY; Braghiroli MI
    Surg Oncol Clin N Am; 2017 Apr; 26(2):313-324. PubMed ID: 28279471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
    Zhang X; Munster PN
    Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.
    Callahan R; Hurvitz S
    Curr Opin Obstet Gynecol; 2011 Feb; 23(1):37-43. PubMed ID: 21500375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.
    Kunte S; Abraham J; Montero AJ
    Cancer; 2020 Oct; 126(19):4278-4288. PubMed ID: 32721042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
    Mohd Sharial MSN; Crown J; Hennessy BT
    Ann Oncol; 2012 Dec; 23(12):3007-3016. PubMed ID: 22865781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
    O'Sullivan CC; Connolly RM
    Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?
    Santa-Maria CA; Nye L; Mutonga MB; Jain S; Gradishar WJ
    Oncology (Williston Park); 2016 Feb; 30(2):148-55. PubMed ID: 26892151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Her2 a paradigm for targeted therapy].
    Marijon H; André F
    Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
    Chen S; Liang Y; Feng Z; Wang M
    BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
    Baez-Vallecillo L; Raghavendra AS; Hess KR; Barcenas CH; Moulder SL; Tripathy D; Valero V; Murthy RK
    Breast Cancer Res Treat; 2019 Jul; 176(1):227-234. PubMed ID: 30977027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
    Gajria D; Chandarlapaty S
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):263-75. PubMed ID: 21342044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
    Huang Y; Fu P; Fan W
    Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.
    Eroglu Z; Tagawa T; Somlo G
    Oncologist; 2014 Feb; 19(2):135-50. PubMed ID: 24436312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.